Sign Out
UserName
Profession Email
Profession Email
Adding empagliflozin to recommended therapy in patients with heart failure with reduced ejection fraction (HFrEF) reduced the risk of HF hospitalization and slowed renal function decline, the EMPEROR-Reduced* trial showed.
MIMS is a trusted, accurate and user-friendly medication information platform. Designed to empower both healthcare professionals and general public to support informed healthcare decisions, our leading drug directory provides clear, reliable information on prescription drugs, over-the-counter medications and other medical resources.
Jangan lewatkan informasi terkini di dunia kesehatan
Lanjutkan dengan Google
Daftar dengan Email
Sudah menjadi anggota?
Masuk
